Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: A prospective case series

Eye

Volumn 23, Issue 5, 2009, Pages 1150-1154

  Atmani, K ^a   Coscas, F ^a   Coscas, G ^a   Soubrane, G ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Age related macular degeneration; Choroidal neovascularisation; Pegaptanib

Indexed keywords

PEGAPTANIB;

ADULT; AGED; ANASTOMOSIS; ANGIOGRAPHY; ARTICLE; CASE STUDY; CLINICAL TRIAL; CORRELATIONAL STUDY; DIAGNOSTIC IMAGING; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; FRANCE; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SCANNING LASER OPHTHALMOSCOPY; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 65949116798     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.194     Document Type: Article

References (11)

1. Resnikoff S, Pascolini D, Etyáale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-851.
2. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-1642.
3. Gonzales CR, for the VEGF Inhibition Study in Ocular Neovascularisation (VISION) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 2005; 25: 815-827.
4. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351 : 2805-2816.
5. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trialsFTAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117: 1329-1345.
6. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 2000; 20: 325-330.
7. Bermig J, Tylla H, Jochmann C, Nestler A, Wolf S. Angiographic findings in patients with exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002; 240: 169-175.
8. Olsen TW, Feng X, Kasper TJ, Rath PP, Steuer ER. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. Ophthalmology 2004; 111: 250-255.
9. QLT Inc. QLT announces two year results of Visudyne in Occult (VIO) Trial; September 20 2005b. http:// www.qltinc.com/Qltinc/pages/pagespressdetail. cfm?PressID=252&YearRange=2005& InternetPageID=31.Accessed January 29, 2007.
10. Lupovitch J, Quiram PA, Hassan TS, Williams GA. Macugen as primary therapy for AMD lesions of all angiographic subtypes [abstract]. Invest Ophthalmol Vis Sci 2006; 47: E Abstract 5217.
11. Kirsch LS, Hairston RJ. Macugen in the treatment of exudative age-related macular degeneration: Experience at the Eye Institute of West Florida. Paper presented at Euretina 2006; May 18-21 Lisbon, Portugal, 2006.